Viatris INC (VTRS) — SEC Filings

Overview

Viatris INC (VTRS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 24, 2026: This Form 4 filing, dated March 24, 2026, indicates that Paul Campbell, a reporting person for Viatris Inc., has filed a statement of changes in beneficial ownership of securities. While the filing itself doesn't detail specific transactions, it signals that an insider's holdings have changed. This

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 2 bearish, 27 neutral. The dominant filing sentiment for Viatris INC is neutral.

Filing Type Overview

Viatris INC (VTRS) has filed 1 4, 1 144, 10 8-K, 2 8-K/A, 5 10-Q, 2 10-K/A, 2 10-K, 4 SC 13G/A, 1 DEF 14A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Viatris Insider Paul Campbell Files Form 4 on Ownership Changes — 4 · Mar 24, 2026
  This Form 4 filing, dated March 24, 2026, indicates that Paul Campbell, a reporting person for Viatris Inc., has filed a statement of changes in beneficial owne
• Viatris Insider Paul Campbell Files for Proposed Securities Sale — 144 · Mar 23, 2026
  This 144 filing indicates that Paul Campbell, a reporting person for Viatris Inc., intends to sell securities of the company. While the filing doesn't specify t
• 8-K Filing — 8-K · Dec 8, 2025
• Viatris Inc. Amends Director/Officer Filings — 8-K/A · Dec 5, 2025 Risk: medium
  Viatris Inc. filed an amendment (8-K/A) on December 5, 2025, to a previous report dated August 4, 2025. This amendment pertains to the departure of directors or
• Viatris Inc. Files 8-K on Financials and Operations — 8-K · Nov 6, 2025 Risk: low
  Viatris Inc. filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes
• Viatris Inc. Files 8-K with Corporate Updates — 8-K · Oct 24, 2025 Risk: low
  Viatris Inc. filed an 8-K on October 24, 2025, reporting several items including amendments to its articles of incorporation or bylaws, shareholder nominations
• Viatris Swings to $1.2B Loss Amid Revenue Decline — 10-Q · Aug 7, 2025 Risk: high
  Viatris Inc. reported a net loss of $1.2 billion for the three months ended June 30, 2025, a significant decline from a net income of $300 million in the prior-
• Viatris Inc. Announces Board Changes and Officer Compensation — 8-K · Aug 5, 2025 Risk: low
  On August 4, 2025, Viatris Inc. filed an 8-K report detailing several key events. The company announced the departure of Director James M. "Jim" Smith, effectiv
• Viatris Inc. Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
  Viatris Inc. filed its 10-Q for the period ending March 31, 2025. The filing covers the first quarter of 2025 and provides financial details for the company, wh
• Viatris Inc. Files 8-K on Officer Changes and Financials — 8-K · May 5, 2025 Risk: low
  Viatris Inc. filed an 8-K on May 5, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, a
• Viatris Inc. Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: low
  Viatris Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 30, 2025, provides updated in
• Viatris Inc. Files 2024 10-K Report — 10-K · Feb 27, 2025 Risk: medium
  Viatris Inc. filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, for
• Viatris Inc. Files 8-K on Director and Officer Changes — 8-K · Dec 6, 2024 Risk: medium
  On December 6, 2024, Viatris Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Viatris Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 7, 2024 Risk: medium
  Viatris Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing covers financial performance and operational upda
• Viatris Inc. DEF 14A: Executive Compensation Details — DEF 14A · Oct 25, 2024 Risk: low
  Viatris Inc. filed its DEF 14A on October 25, 2024, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2023. The
• Viatris Inc. Enters Material Definitive Agreement — 8-K · Sep 27, 2024 Risk: medium
  On September 27, 2024, Viatris Inc. entered into a material definitive agreement, which also created a direct financial obligation for the registrant. The filin
• Viatris Inc. Files 8-K for Routine Disclosures — 8-K · Sep 4, 2024 Risk: low
  On September 4, 2024, Viatris Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specifi
• Viatris Q2 Revenue Dips Slightly to $3.68B — 10-Q · Aug 8, 2024 Risk: medium
  Viatris Inc. reported its Q2 2024 results, with total revenues for the three months ended June 30, 2024, reaching $3.68 billion. This represents a slight decrea
• Viatris Inc. Completes Asset Acquisition/Disposition — 8-K · Jul 3, 2024 Risk: medium
  On July 3, 2024, Viatris Inc. filed an 8-K report indicating the completion of an acquisition or disposition of assets. The filing does not specify the nature o
• Viatris Inc. Files 8-K: Board Changes and Executive Compensation Updates — 8-K · Jun 3, 2024 Risk: medium
  On June 3, 2024, Viatris Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of ne
• Viatris Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Viatris Inc (VTRS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Viatris Inc. reported financial results for the quarter ended March 31, 2024. Th
• Viatris Inc. Files Amendment No. 1 to Annual Report on Form 10-K — 10-K/A · Apr 26, 2024 Risk: low
  Viatris Inc (VTRS) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Viatris Inc. filed an amendment (10-K/A) to its annual report for the
• Viatris Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
  Viatris Inc (VTRS) filed a Annual Report (10-K) with the SEC on February 28, 2024. Viatris Inc. filed its annual report on Form 10-K for the fiscal year ended D
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• DAVIS SELECTED ADVISERS Discloses Passive Stake in Viatris (VTRS) — SC 13G · Feb 9, 2024 Risk: low
  DAVIS SELECTED ADVISERS, an investment management firm, filed an SC 13G on February 9, 2024, disclosing its ownership of Viatris Inc. (VTRS) common stock as of
• Viatris Amends Material Agreement Filing (8-K/A) — 8-K/A · Jan 30, 2024
  Viatris Inc. filed an 8-K/A on January 30, 2024, amending a previous filing from October 1, 2023. This amendment relates to an "Entry into a Material Definitive
• State Street Corp. Updates Passive Stake in Viatris Inc. — SC 13G/A · Jan 30, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 30, 2024, indicating its ownership of Viatris Inc. common stock as
• BlackRock Amends Viatris Stake, Maintains Passive Investment — SC 13G/A · Jan 26, 2024
  BlackRock, Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Viatris Inc. as of December 31, 2023. This filing, Amendment No. 3, i

Risk Profile

Risk Assessment: Of VTRS's 21 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Viatris INC's most recent 10-Q filing (Aug 7, 2025):

• Revenue: $3.8B
• Net Income: -$1.2B

Key Executives

• James M. "Jim" Smith
• Dr. Brenda J. Smith
• Ms. Amy E. W. Peterson
• Michael Goettler
• Scott A.

Industry Context

The pharmaceutical industry is highly competitive, with significant R&D investment, patent expirations, and increasing generic competition. Viatris operates in a segment facing intense pricing pressures from payers and governments, alongside evolving regulatory landscapes.

Top Tags

corporate-governance (5) · amendment (5) · pharmaceuticals (5) · executive-compensation (4) · Pharmaceuticals (3) · 10-Q (3) · Viatris (3) · institutional-ownership (3) · passive-investment (3) · officer-changes (2)

Key Numbers

• Net Loss: $1.2B — Q2 2025 net loss, a significant swing from $300M net income in Q2 2024.
• Revenue: $3.8B — Q2 2025 revenue, a 7.3% decrease from $4.1B in Q2 2024.
• Revenue Change: -7.3% — Year-over-year revenue decrease for Q2 2025.
• Accumulated Other Comprehensive Loss: $1.8B — As of June 30, 2025, an increase from $1.5B on December 31, 2024.
• Common Shares Outstanding: 1.22B — As of June 30, 2025, a slight increase from 1.21B on December 31, 2024.
• Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
• Filing Date: 2025-05-08 — The date the report was officially submitted to the SEC.
• Fiscal Quarter: 2025 Q1 — Specifies the first quarter of the fiscal year 2025.
• SEC File Number: 001-39695 — Identifies Viatris Inc.'s filings with the SEC.
• EIN: 83-4364296 — Employer Identification Number for Viatris Inc.
• Report Date: 12/06/2024 — Date of earliest event reported
• Fiscal Year End: 2023-12-31 — The period for which executive compensation is reported.
• I.R.S. Employer Identification No.: 83-4364296 — Viatris Inc.'s tax identification number.
• Q2 2024 Revenue: $3.68B — Total revenue for the three months ended June 30, 2024.
• Q2 2023 Revenue: $3.71B — Total revenue for the three months ended June 30, 2023, for comparison.

Related Companies

PFE · TEVA

Frequently Asked Questions